Biocon Ltd., the Bengaluru-based pharmaceutical company, is strategically positioning itself to capitalize on the impending expiration of patents for the blockbuster weight-loss drugs Ozempic and Wegovy, manufactured by Novo Nordisk A/S. With a keen eye on the Canadian market, where these patents are set to lapse next year, Biocon plans to seek regulatory approval for generic versions of these drugs. According to managing director Siddharth Mittal, Canada represents a prime opportunity for the company, which aims to file for approval for generic Ozempic by September. If the process unfolds smoothly, Biocon anticipates securing the green light to commence sales in 2026.
In addition to targeting Canada, Biocon is also exploring opportunities in emerging markets, affirming its commitment to establish itself among the forerunners in the generic medication sector. The company is gearing up to initiate phase-3 trials for semaglutide, the active ingredient in Ozempic and Wegovy, in India, with plans to submit approval requests for the Indian market by the end of next year. With Novo Nordisk controlling about 70 percent of the global market for these obesity drugs, the expiration of its patents could open the floodgates for various competitors, including Biocon.
The firm is not alone in its pursuit of this lucrative market; major players like Teva Pharmaceutical Industries and Gan & Lee Pharmaceutical from China are also positioning themselves to capture a share of the growing demand for generic obesity medications. However, Biocon aims to be the first to launch a semaglutide copycat drug in Canada, a significant goal as other companies may lag in the regulatory approval race.
Biocon’s ambitions further extend to other regions, including Latin America and Asia-Pacific countries, where the consumption of obesity medications remains relatively under-penetrated. Mittal highlighted the substantial potential for market expansion in these regions, aligning the company’s strategy with global trends in obesity management and the rising health consciousness among populations. The recent launch of Wegovy in India by Novo Nordisk underscores the market’s readiness for such medications, with local companies, including Cipla and Torrent Pharmaceuticals, also eyeing the development of their own generic versions.
In this competitive landscape, Biocon’s experience in producing insulin gives it an edge against local competitors. The company believes that while the market may become crowded with generic versions, it does not foresee significant price erosion for Wegovy copies in India, projecting an average price drop of about twenty percent in contrast to the typical 90 percent decline seen for blockbuster drugs following the entry of generics.
As the patent expirations approach, the competitive dynamics of the weight-loss drug market will likely intensify, with multiple players vying for a foothold. Biocon’s strategic focus on regulatory approvals and market entry could well position it as a leader in the burgeoning field of generic obesity treatments, signalling a significant shift in how weight-loss medications are accessed by consumers in emerging markets. The unfolding scenario promises to reshape the pharmaceutical landscape, providing more affordable options for the millions affected by obesity globally.
-Raja Aditya
